No label defined (Q31620)

From lgbtDB
Revision as of 20:55, 13 November 2024 by Superraptor (talk | contribs) (‎Created a new Item)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
No description defined
  • Clinical and Biochemical Outcomes in Transgender Individuals Undergoing Hormone Therapy: Protocol for a Systematic Review.
Language Label Description Also known as
English
No label defined
No description defined
  • Clinical and Biochemical Outcomes in Transgender Individuals Undergoing Hormone Therapy: Protocol for a Systematic Review.

Statements

title
Clinical and Biochemical Outcomes in Transgender Individuals Undergoing Hormone Therapy: Protocol for a Systematic Review. (English)
1 reference
stated in
PubMed
abstract
Monitoring of various clinical outcomes and parameters, such as lipid levels, is recommended in transgender individuals undergoing hormone therapies. (English)
source label
BACKGROUND (English)
subsection NLM category
background section
series ordinal
1
copyright statement
©Emily Sattora, Karen Teelin, Christopher Prendergast, Abigail Smith, James Evans, Aamer Imdad. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.11.2024. (English)
date copyrighted
2024
rights holder
Q31603
Q31605
Q31607
Q31609
Q31610
Q31612
1 reference
stated in
PubMed
However, comprehensive data to inform these recommendations is scarce. (English)
source label
BACKGROUND (English)
subsection NLM category
background section
series ordinal
2
copyright statement
©Emily Sattora, Karen Teelin, Christopher Prendergast, Abigail Smith, James Evans, Aamer Imdad. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.11.2024. (English)
date copyrighted
2024
rights holder
Q31603
Q31605
Q31607
Q31609
Q31610
Q31612
1 reference
stated in
PubMed
This study aims to conduct a systematic review and meta-analysis to synthesize evidence from existing literature on the effect of exogenous hormone therapy on clinical and biochemical outcomes for transgender adolescents and adults. (English)
source label
OBJECTIVE (English)
subsection NLM category
objective section
series ordinal
3
copyright statement
©Emily Sattora, Karen Teelin, Christopher Prendergast, Abigail Smith, James Evans, Aamer Imdad. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.11.2024. (English)
date copyrighted
2024
rights holder
Q31603
Q31605
Q31607
Q31609
Q31610
Q31612
1 reference
stated in
PubMed
We will search multiple electronic databases and will include prospective and retrospective observational studies with and without a control group. (English)
source label
METHODS (English)
subsection NLM category
methods section
series ordinal
4
copyright statement
©Emily Sattora, Karen Teelin, Christopher Prendergast, Abigail Smith, James Evans, Aamer Imdad. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.11.2024. (English)
date copyrighted
2024
rights holder
Q31603
Q31605
Q31607
Q31609
Q31610
Q31612
1 reference
stated in
PubMed
The study population will include transgender individuals undergoing hormone therapy with testosterone or estrogen. (English)
source label
METHODS (English)
subsection NLM category
methods section
series ordinal
5
copyright statement
©Emily Sattora, Karen Teelin, Christopher Prendergast, Abigail Smith, James Evans, Aamer Imdad. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.11.2024. (English)
date copyrighted
2024
rights holder
Q31603
Q31605
Q31607
Q31609
Q31610
Q31612
1 reference
stated in
PubMed
Comparisons will include age-matched, cisgender individuals and changes from baseline. (English)
source label
METHODS (English)
subsection NLM category
methods section
series ordinal
6
copyright statement
©Emily Sattora, Karen Teelin, Christopher Prendergast, Abigail Smith, James Evans, Aamer Imdad. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.11.2024. (English)
date copyrighted
2024
rights holder
Q31603
Q31605
Q31607
Q31609
Q31610
Q31612
1 reference
stated in
PubMed
Primary outcomes include changes in or the development of abnormal lipid parameters. (English)
source label
METHODS (English)
subsection NLM category
methods section
series ordinal
7
copyright statement
©Emily Sattora, Karen Teelin, Christopher Prendergast, Abigail Smith, James Evans, Aamer Imdad. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.11.2024. (English)
date copyrighted
2024
rights holder
Q31603
Q31605
Q31607
Q31609
Q31610
Q31612
1 reference
stated in
PubMed
Secondary outcomes include BMI, weight, height, and blood pressure for age, serum testosterone or estrogen levels, and development of disease including hypertension, diabetes, fatty liver disease, obesity, adverse cardiac events, as well as all-cause mortality. (English)
source label
METHODS (English)
subsection NLM category
methods section
series ordinal
8
copyright statement
©Emily Sattora, Karen Teelin, Christopher Prendergast, Abigail Smith, James Evans, Aamer Imdad. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.11.2024. (English)
date copyrighted
2024
rights holder
Q31603
Q31605
Q31607
Q31609
Q31610
Q31612
1 reference
stated in
PubMed
The meta-analysis will pool the studies where applicable, and meta-regressions will be conducted to evaluate effect modifiers. (English)
source label
METHODS (English)
subsection NLM category
methods section
series ordinal
9
copyright statement
©Emily Sattora, Karen Teelin, Christopher Prendergast, Abigail Smith, James Evans, Aamer Imdad. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.11.2024. (English)
date copyrighted
2024
rights holder
Q31603
Q31605
Q31607
Q31609
Q31610
Q31612
1 reference
stated in
PubMed
The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach will be used to evaluate the overall certainty of evidence. (English)
source label
METHODS (English)
subsection NLM category
methods section
series ordinal
10
copyright statement
©Emily Sattora, Karen Teelin, Christopher Prendergast, Abigail Smith, James Evans, Aamer Imdad. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.11.2024. (English)
date copyrighted
2024
rights holder
Q31603
Q31605
Q31607
Q31609
Q31610
Q31612
1 reference
stated in
PubMed
We will summarize the selection of the eligible studies using a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart. (English)
source label
RESULTS (English)
subsection NLM category
results section
series ordinal
11
copyright statement
©Emily Sattora, Karen Teelin, Christopher Prendergast, Abigail Smith, James Evans, Aamer Imdad. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.11.2024. (English)
date copyrighted
2024
rights holder
Q31603
Q31605
Q31607
Q31609
Q31610
Q31612
1 reference
stated in
PubMed
The results will be presented in a table summarizing the evidence. (English)
source label
RESULTS (English)
subsection NLM category
results section
series ordinal
12
copyright statement
©Emily Sattora, Karen Teelin, Christopher Prendergast, Abigail Smith, James Evans, Aamer Imdad. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.11.2024. (English)
date copyrighted
2024
rights holder
Q31603
Q31605
Q31607
Q31609
Q31610
Q31612
1 reference
stated in
PubMed
Data collection is ongoing, and the paper is expected to be published in Spring 2025. (English)
source label
RESULTS (English)
subsection NLM category
results section
series ordinal
13
copyright statement
©Emily Sattora, Karen Teelin, Christopher Prendergast, Abigail Smith, James Evans, Aamer Imdad. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.11.2024. (English)
date copyrighted
2024
rights holder
Q31603
Q31605
Q31607
Q31609
Q31610
Q31612
1 reference
stated in
PubMed
This systematic review will summarize and evaluate the evidence of the clinical and biochemical outcomes associated with hormone therapies for transgender individuals. (English)
source label
CONCLUSIONS (English)
subsection NLM category
conclusion section
series ordinal
14
copyright statement
©Emily Sattora, Karen Teelin, Christopher Prendergast, Abigail Smith, James Evans, Aamer Imdad. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.11.2024. (English)
date copyrighted
2024
rights holder
Q31603
Q31605
Q31607
Q31609
Q31610
Q31612
1 reference
stated in
PubMed
PROSPERO CRD42024483138; https://tinyurl.com/yc4sfvnb. (English)
source label
TRIAL REGISTRATION (English)
subsection NLM category
background section
series ordinal
15
copyright statement
©Emily Sattora, Karen Teelin, Christopher Prendergast, Abigail Smith, James Evans, Aamer Imdad. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.11.2024. (English)
date copyrighted
2024
rights holder
Q31603
Q31605
Q31607
Q31609
Q31610
Q31612
1 reference
stated in
PubMed
PRR1-10.2196/57931. (English)
source label
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) (English)
subsection NLM category
no value
series ordinal
16
copyright statement
©Emily Sattora, Karen Teelin, Christopher Prendergast, Abigail Smith, James Evans, Aamer Imdad. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.11.2024. (English)
date copyrighted
2024
rights holder
Q31603
Q31605
Q31607
Q31609
Q31610
Q31612
1 reference
stated in
PubMed
date published
12 November 2024
1 reference
stated in
PubMed
date issued
12 November 2024
1 reference
stated in
PubMed
volume
13
1 reference
stated in
PubMed
page(s)
e57931
1 reference
stated in
PubMed
page start
e57931
1 reference
stated in
PubMed
 
Retrieved from "https://lgbtdb.wikibase.cloud/w/index.php?title=Item:Q31620&oldid=188556"